Annexin A5 levels in midtrimester amniotic fluid: association with intrauterine growth restriction.
OBJECTIVE
The purpose of this study was to determine whether amniotic fluid levels of annexin A5 (AF-AnxA5) may be associated with intrauterine growth restriction (IUGR).


METHODS
Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks' gestation and annexin A5 (AnxA5) levels were determined with enzyme-linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort.


RESULTS
AF-AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF-AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF-AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR (P = .023).


CONCLUSIONS
AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF-AnxA5 may be a useful marker for identifying pregnancy abnormalities.
Department of Obstetrics & Gynecology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.
Peter
P
Van Eerden
Xiao-Xuan
XX
Wu
Cynthia
C
Chazotte
Jacob H
JH
Rand
D000328:Adult; D000649:Amniocentesis; D000653:Amniotic Fluid / Q000378:metabolism*; D017304:Annexin A5 / Q000378:metabolism*; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005317:Fetal Growth Retardation / Q000209:etiology / Q000378:metabolism*; D005865:Gestational Age; D006801:Humans; D016014:Linear Models; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D012306:Risk
D017304:Annexin A5